Register entry
argenx BV
- Registered sites
- 1
- Drug products
- 3
- Live patents
- 0
- Countries
- 1
- Base
- Belgium
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Finished drug manufacture
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| argenx BV | GentBelgium | Finished drug manufacture | 3015102398 |
Catalogue
Marketed products
3Showing 3 of 3.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| VYVGART | EFGARTIGIMOD ALFA | INJECTION | BLA |
| VYVGART Hytrulo | efgartigimod alfa and hyaluronidase (human recombinant) | INJECTION, SOLUTION | BLA |
| VYVGART Hytrulo | efgartigimod alfa and hyaluronidase (human recombinant) | INJECTION, SOLUTION | BLA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.